November 21, 2026

Biotech Funding in October 2026: A Dated Ledger of IPOs, Venture Raises and Pharma Deals

Biotech Funding in October 2026: A Dated Ledger of IPOs, Venture Raises and Pharma Deals

Biotech funding is busy in October 2026: BioPharma Dive counts 23 drug developers that have gone public this year, and the first ten days of October produced two IPO pricings, a $2.6 billion venture fundraise and several multibillion-dollar pharma deals. What follows is a dated ledger of those events, with the numbers, the caveats and the parts nobody can yet judge. It describes what happened and is not investment advice.

The week at a glance

Everything in the table below comes from trade-press reports of company announcements and filings, listed at the end. The figures are as reported by BioPharma Dive and Fierce Biotech, not taken from the SEC filings directly.

Date (2026) Event Headline number
Oct 1 Sanofi and Regeneron expand their alliance $1B upfront, up to $7B milestones
Oct 2 Novartis licenses RNA technology from Abogen Biosciences $575M upfront, up to $7.8B total
Oct 5 Shionogi to acquire IntraBio $2B in cash
Oct 6 Forbion announces two venture funds EUR 2.3B (about $2.6B)
Oct 8 Viatris to acquire Pacira BioSciences About $1.65B, $36.50 per share
Oct 8 Iambic Therapeutics sets IPO terms 9.4M shares at $15 to $17
Oct 9 TRex Bio and Retension Pharmaceuticals price IPOs $116.7M and $45M gross
Biotech laboratory bench with pipettes and sample tubes
A working biotech bench. AI-generated image.

The IPO window

BioPharma Dive reports that 23 drug developers have gone public in 2026, six of them in immune disease, and cites a William Blair report describing public-market investment in biotechs as having accelerated at an “unprecedented clip” this year. It also notes a similar number of reverse mergers and a few SPAC deals. For scale, the outlet’s IPO tracker recalls the 2021 peak, when more than 100 biotechs raised nearly $15 billion; it gives no 2026 total, so I do not compare the two years.

The two newest pricings show what the window looks like at the small end. According to Fierce Biotech:

  • TRex Bio (Nasdaq: TRXB) sold 8.3 million shares at $14, the bottom of its $14 to $16 range, for $116.7 million gross. The company develops regulatory T-cell modulators; about $90 million of proceeds is earmarked for a phase 2 trial in atopic dermatitis and related diseases, and topline phase 1 data are expected in mid-2027. Eli Lilly paid $55 million in 2023 for a license option.
  • Retension Pharmaceuticals (Nasdaq: RTSN) sold 3.8 million shares at $12, the midpoint of its range, for $45 million gross. Its lead drug is an oral PDE-5 inhibitor designed to lower blood pressure.

Fierce also reports that Iambic Therapeutics filed terms the day before for 9.4 million shares at $15 to $17, about $135 million net at the midpoint, and that City Therapeutics planned a $158.3 million offering. Terms are plans until an offering prices, so those two remain open items. One more detail: the TRex gross proceeds quoted do not equal shares times price exactly (8.3 million times $14 is about $116.2 million), which probably reflects rounding of the share count.

Venture money and the European picture

Forbion, described by BioPharma Dive as the largest European venture investor focused only on life sciences, announced on October 6 that it raised EUR 2.3 billion across Forbion Growth Opportunities IV and Forbion Ventures Fund VIII. That is its largest raise yet, against $2.2 billion in 2024, and it brings assets under management to EUR 7.5 billion. Investors include Dutch pension managers MN and PGGM, the Kauffman Foundation, Germany’s KfW Capital and Eli Lilly.

The firm’s co-founder Sander Slootweg said the raise gives it “significant dry powder in a market characterized by a general shortage of capital.” That is a notable pairing with the IPO numbers: money is available for the winners, and scarce for the rest. The same article says nine pharma board chairs urged policy changes in September to speed drug development and attract investment to Europe, and that the US continues to attract a larger share of biotech venture dollars, with some activity shifting to China.

Big pharma deals: three kinds

The week’s transactions fall into three different structures, which are easy to confuse in headlines.

Acquisitions

Viatris agreed to buy Pacira BioSciences for $36.50 a share in cash, a 45% premium to the October 7 close, with closing expected by the end of 2026 (BioPharma Dive). Pacira’s two main drugs, Exparel and Zilretto, had $692 million in combined 2025 sales. Shionogi agreed to pay $2 billion in cash for the rare-disease company IntraBio, whose Aqneursa treats Niemann-Pick disease type C and, since September, Ataxia-Telangiectasia; IntraBio had $68 million in 2025 sales per Shionogi (BioPharma Dive). No closing date was reported for the Shionogi deal.

Licensing with an option

Novartis is paying Abogen $575 million upfront for access to its RNA drug-making technology and an option on a lead program, ABO2203, an mRNA-encoded T cell engager aimed at CD3 and CD19. Up to $7.2 billion more depends on milestones, bringing the headline to $7.8 billion (BioPharma Dive). The outlet counts at least a dozen licensing deals for multispecific biologics between Western drugmakers and Chinese developers. Milestone totals are the maximum if everything succeeds; the upfront is the money that is certain.

Co-development alliances

Sanofi and Regeneron expanded their relationship, with Regeneron receiving $1 billion upfront and eligible for up to $7 billion more. Regeneron leads R&D on four long-acting antibodies aimed at IL-4, IL-13 or both, Sanofi leads commercialization, and costs and profits are split evenly. The lead candidate, REGN20423, is in an early clinical trial in eczema, and the other three are expected to enter human testing next year (BioPharma Dive). The existing Dupixent profit share is unchanged.

Glass towers of a city financial district at dusk
Where the money comes from. AI-generated image.

How to read a biotech deal headline

  1. Separate upfront from total. The Novartis headline of $7.8 billion is 7% upfront. Milestones are contingent.
  2. Check the structure. A license, an option, an acquisition and a collaboration carry different obligations and different odds of ever reaching patients.
  3. Note the stage. REGN20423 is in an early trial. Early assets fail often, and the big numbers reflect hoped-for outcomes.
  4. Distinguish announced from closed. Viatris and Pacira are expected to close by year end, and approval of acquisitions can change terms or timing.
  5. Watch the pricing versus the range. TRex priced at the low end of its range and Retension at the midpoint, which says something about demand for those particular offerings.

Where this leaves the sector

The documented facts support a modest conclusion. Public investors are funding new listings, large drugmakers are paying real money for pipelines and platforms, and a big European venture firm says capital is still short for most companies. Both sides can be true at once, and the sources I could access do not provide the sector-wide numbers that would show how concentrated the funding is. None of this predicts how any stock or private company will perform, and nothing here should be taken as a recommendation to buy or sell.

DNA sequencing machine with blue indicator lights
Sequencing hardware, one of the things funding rounds pay for. AI-generated image.

Plain-language glossary for the terms in this ledger

  • Upfront payment. Cash the licensee pays when the deal is signed. It is the only part that is certain.
  • Milestone. A payment triggered by an event such as starting a trial, winning approval or reaching a sales threshold. Most potential milestones are never paid, because most drug programs do not reach the market.
  • Option. The right, not the obligation, to license a program later, usually after data arrive. Novartis holds one on Abogen’s lead program.
  • Gross and net proceeds. Gross is what investors pay for the shares. Net is what the company keeps after underwriting fees and expenses; Fierce’s Iambic figures show $150 million gross against $135 million net at the midpoint.
  • Greenshoe or underwriter option. An extra block of shares underwriters can buy, which raises proceeds if demand is strong.
  • Premium. How far an acquisition price sits above the target’s recent share price. Viatris is paying 45% above the October 7 close.

Those definitions are standard industry usage rather than anything specific to one source, but each example above is drawn from the reports I cited.

What the record does not show

Several things people tend to assume are not in the material I could read. There is no total for 2026 IPO proceeds and no comparison with 2025. Fierce Biotech mentions “record-breaking” 2026 listings from Parabilis Medicines and Kailera Therapeutics but gives no figures. Nor do the reports say how the newly listed shares have traded after pricing. The week’s deals are also all announcements: only the passage of time will show which close on schedule and which drugs reach patients.

One more limit: this is one week of news, not a trend line. Ten days with many deals can be followed by a quiet month, and a single ledger cannot show which. Readers who want the longer view should look at the full IPO tracker and the original filings rather than at any single article, including this one.

Sources

429 Posts

Peter Kalafatis writes and edits X9M8. He holds a bachelor's degree from LIU Post and a master's in Media Studies from The New School, with academic work in the philosophy of science, human behavior, AI, and memetics.

View All Posts

Leave a Reply

Your email address will not be published. Required fields are marked *